Today NBE-Therapeutics announces publication of a peer-reviewed scientific article entitled "Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency" authored by Roger R. Beerli (CSO, NBE-Therapeutics) and co-workers in PLoS One 10(7), e0131177, which can freely be downloaded here. The paper contains validating data on tumor killing activity for anti-HER-2-maytansine and anti-CD30-MMAE ADCs generated using NBE-Therapeutics' site-specific payload conjugation technology, called SMAC-TechnologyTM (SMAC = sortase mediated antibody conjugation).